

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 18 2000

TECH CENTER 1600/2900

In Re Application of: EISENBACH-SCHWARTZ

Art Unit: 1647

Application No.: 09/218,277

Examiner: S. Turner

Filed: December 22, 1998

Washington, D.C.

For: T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

Atty.'s Docket: EIS-SCHWARTZ=1A

Date: September 14, 2000

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment [ ]  
in the above-identified application.

[XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted

[ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

[XX] No additional fee is required.

[ ] The fee has been calculated as shown below:

|        | (Col. 1)                                  |       | (Col. 2)                              |  | (Col. 3)                   |
|--------|---|-------|---------------------------------------|--|----------------------------|
|        | CLAIMS<br>REMAINING<br>AFTER<br>AMENDMENT |       | HIGHEST NO.<br>PREVIOUSLY<br>PAID FOR |  | PRESENT<br>EXTRA<br>EQUALS |
| TOTAL  | * 17                                      | MINUS | ** 30                                 |  | 0                          |
| INDEP. | * 1                                       | MINUS | *** 3                                 |  | 0                          |

FIRST PRESENTATION OF MULTIPLE DEP. CLAIM

ADDITIONAL FEE TOTAL

## SMALL ENTITY

|   | RATE | ADDITIONAL<br>FEE |
|---|------|-------------------|
| x | 9    | \$                |
| x | 39   | \$                |
| + | 130  | \$                |
|   |      | \$                |

OR

## OTHER THAN SMALL ENTITY

|   | RATE | ADDITIONAL<br>FEE |
|---|------|-------------------|
| x | 18   | \$                |
| x | 78   | \$                |
| + | 260  | \$                |
|   |      | \$                |

OR

TOTAL

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

## Small Entity

## Response Filed Within

[ ] First - \$ 55.00  
 [ ] Second - \$ 190.00  
 [ ] Third - \$ 435.00  
 [ ] Fourth - \$ 680.00

## Month After Time Period Set

## Other Than Small Entity

## Response Filed Within

[ ] First - \$ 110.00  
 [ ] Second - \$ 380.00  
 [ ] Third - \$ 870.00  
 [ ] Fourth - \$ 1360.00

## Month After Time Period Set

[ ] Less fees (\$ ) already paid for month(s) extension of time on .

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ .

[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ .

[ ] A check in the amount of \$ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Roger L. Browdy  
Registration No. 25,618

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197

UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

EISENBACH-SCHWARTZ et al

Appln. No.: 09/218,277

Filed: December 22, 1998

For: T-CELLS, NERVOUS SYSTEM-  
SPECIFIC ANTIGENS AND  
THEIR USES



Art Unit: 1647

Examiner: S. Turner

Washington, D.C.

September 14, 2000

Atty. Docket:  
EIS-SCHWARTZ=1A

3/14  
12.7  
9/19/00

AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

Responsive to the Office Action of August 15, 2000,  
Paper No. 13, primarily in the nature of a requirement for  
restriction, please amend as follows:

IN THE CLAIMS

Cancel claims 1 and 2 and substitute therefor new  
claim 16 as follows:

--16. A method of ameliorating the effects of  
injury or disease on the central nervous system or peripheral  
nervous system, by preventing or inhibiting axonal  
degeneration and/or promoting nerve regeneration, comprising  
administering to a human in need thereof an effective amount

B1  
sub E  
2

11-12 T cells wd.  
13 not p